11th May 2021 17:50
Physiomics PLC - oncology consultant based in Oxford - Awarded its first contract by Zurich-based biopharmaceutical company Numab Therapeutics, which is focused on developing biotherapeutics for chronic inflammation and cancer.
"We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team," notes Chief Executive Officer Jim Millen.
Current stock price: 5.91 pence
Year-to-date change: down 20%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics